TPI 287: Phase I started

Cortice began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate 2, 6.3 and 20 mg/m 2 IV TPI 287 every 3 weeks for 9 weeks in about 33 patients with mild to moderate A...